These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
226 related articles for article (PubMed ID: 24725942)
1. Phagocytic cells contribute to the antibody-mediated elimination of pulmonary-infected SARS coronavirus. Yasui F; Kohara M; Kitabatake M; Nishiwaki T; Fujii H; Tateno C; Yoneda M; Morita K; Matsushima K; Koyasu S; Kai C Virology; 2014 Apr; 454-455():157-68. PubMed ID: 24725942 [TBL] [Abstract][Full Text] [Related]
2. Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection. Liu L; Wei Q; Lin Q; Fang J; Wang H; Kwok H; Tang H; Nishiura K; Peng J; Tan Z; Wu T; Cheung KW; Chan KH; Alvarez X; Qin C; Lackner A; Perlman S; Yuen KY; Chen Z JCI Insight; 2019 Feb; 4(4):. PubMed ID: 30830861 [TBL] [Abstract][Full Text] [Related]
3. Complete protection against severe acute respiratory syndrome coronavirus-mediated lethal respiratory disease in aged mice by immunization with a mouse-adapted virus lacking E protein. Fett C; DeDiego ML; Regla-Nava JA; Enjuanes L; Perlman S J Virol; 2013 Jun; 87(12):6551-9. PubMed ID: 23576515 [TBL] [Abstract][Full Text] [Related]
4. Virus-specific memory CD8 T cells provide substantial protection from lethal severe acute respiratory syndrome coronavirus infection. Channappanavar R; Fett C; Zhao J; Meyerholz DK; Perlman S J Virol; 2014 Oct; 88(19):11034-44. PubMed ID: 25056892 [TBL] [Abstract][Full Text] [Related]
5. Cellular immune responses to severe acute respiratory syndrome coronavirus (SARS-CoV) infection in senescent BALB/c mice: CD4+ T cells are important in control of SARS-CoV infection. Chen J; Lau YF; Lamirande EW; Paddock CD; Bartlett JH; Zaki SR; Subbarao K J Virol; 2010 Feb; 84(3):1289-301. PubMed ID: 19906920 [TBL] [Abstract][Full Text] [Related]
6. T cell responses are required for protection from clinical disease and for virus clearance in severe acute respiratory syndrome coronavirus-infected mice. Zhao J; Zhao J; Perlman S J Virol; 2010 Sep; 84(18):9318-25. PubMed ID: 20610717 [TBL] [Abstract][Full Text] [Related]
7. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. Pinto D; Park YJ; Beltramello M; Walls AC; Tortorici MA; Bianchi S; Jaconi S; Culap K; Zatta F; De Marco A; Peter A; Guarino B; Spreafico R; Cameroni E; Case JB; Chen RE; Havenar-Daughton C; Snell G; Telenti A; Virgin HW; Lanzavecchia A; Diamond MS; Fink K; Veesler D; Corti D Nature; 2020 Jul; 583(7815):290-295. PubMed ID: 32422645 [TBL] [Abstract][Full Text] [Related]
8. Structural basis for potent cross-neutralizing human monoclonal antibody protection against lethal human and zoonotic severe acute respiratory syndrome coronavirus challenge. Rockx B; Corti D; Donaldson E; Sheahan T; Stadler K; Lanzavecchia A; Baric R J Virol; 2008 Apr; 82(7):3220-35. PubMed ID: 18199635 [TBL] [Abstract][Full Text] [Related]
9. T cell-mediated immune response to respiratory coronaviruses. Channappanavar R; Zhao J; Perlman S Immunol Res; 2014 Aug; 59(1-3):118-28. PubMed ID: 24845462 [TBL] [Abstract][Full Text] [Related]
11. Cross-reactive neutralization of SARS-CoV-2 by serum antibodies from recovered SARS patients and immunized animals. Zhu Y; Yu D; Han Y; Yan H; Chong H; Ren L; Wang J; Li T; He Y Sci Adv; 2020 Nov; 6(45):. PubMed ID: 33036961 [TBL] [Abstract][Full Text] [Related]
12. Protection of mammalian cells from severe acute respiratory syndrome coronavirus infection by equine neutralizing antibody. Wang X; Ni B; Du X; Zhao G; Gao W; Shi X; Zhang S; Zhang L; Wang D; Luo D; Xing L; Jiang H; Li W; Jiang M; Mao L; He Y; Xiao Y; Wu Y Antivir Ther; 2005; 10(5):681-90. PubMed ID: 16152762 [TBL] [Abstract][Full Text] [Related]
13. Prior infection and passive transfer of neutralizing antibody prevent replication of severe acute respiratory syndrome coronavirus in the respiratory tract of mice. Subbarao K; McAuliffe J; Vogel L; Fahle G; Fischer S; Tatti K; Packard M; Shieh WJ; Zaki S; Murphy B J Virol; 2004 Apr; 78(7):3572-7. PubMed ID: 15016880 [TBL] [Abstract][Full Text] [Related]
14. Severe acute respiratory syndrome coronaviruses with mutations in the E protein are attenuated and promising vaccine candidates. Regla-Nava JA; Nieto-Torres JL; Jimenez-Guardeño JM; Fernandez-Delgado R; Fett C; Castaño-Rodríguez C; Perlman S; Enjuanes L; DeDiego ML J Virol; 2015 Apr; 89(7):3870-87. PubMed ID: 25609816 [TBL] [Abstract][Full Text] [Related]
15. Effect of mucosal and systemic immunization with virus-like particles of severe acute respiratory syndrome coronavirus in mice. Lu B; Huang Y; Huang L; Li B; Zheng Z; Chen Z; Chen J; Hu Q; Wang H Immunology; 2010 Jun; 130(2):254-61. PubMed ID: 20406307 [TBL] [Abstract][Full Text] [Related]
16. Receptor-binding domain of SARS-CoV spike protein induces long-term protective immunity in an animal model. Du L; Zhao G; He Y; Guo Y; Zheng BJ; Jiang S; Zhou Y Vaccine; 2007 Apr; 25(15):2832-8. PubMed ID: 17092615 [TBL] [Abstract][Full Text] [Related]
17. Severe acute respiratory syndrome-associated coronavirus vaccines formulated with delta inulin adjuvants provide enhanced protection while ameliorating lung eosinophilic immunopathology. Honda-Okubo Y; Barnard D; Ong CH; Peng BH; Tseng CT; Petrovsky N J Virol; 2015 Mar; 89(6):2995-3007. PubMed ID: 25520500 [TBL] [Abstract][Full Text] [Related]
18. A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice. Yang ZY; Kong WP; Huang Y; Roberts A; Murphy BR; Subbarao K; Nabel GJ Nature; 2004 Apr; 428(6982):561-4. PubMed ID: 15024391 [TBL] [Abstract][Full Text] [Related]
19. Prior immunization with severe acute respiratory syndrome (SARS)-associated coronavirus (SARS-CoV) nucleocapsid protein causes severe pneumonia in mice infected with SARS-CoV. Yasui F; Kai C; Kitabatake M; Inoue S; Yoneda M; Yokochi S; Kase R; Sekiguchi S; Morita K; Hishima T; Suzuki H; Karamatsu K; Yasutomi Y; Shida H; Kidokoro M; Mizuno K; Matsushima K; Kohara M J Immunol; 2008 Nov; 181(9):6337-48. PubMed ID: 18941225 [TBL] [Abstract][Full Text] [Related]
20. Development of vaccines and passive immunotherapy against SARS coronavirus using mouse and SCID-PBL/hu mouse models. Okada M; Takemoto Y; Okuno Y; Hashimoto S; Fukunaga Y; Tanaka T; Kita Y; Kuwayama S; Muraki Y; Kanamaru N; Takai H; Okada C; Sakaguchi Y; Furukawa I; Yamada K; Izumiya M; Yoshida S; Matsumoto M; Kase T; Peiris JS; DeMello DE; Chen PJ; Yamamoto N; Yoshinaka Y; Nomura T; Ishida I; Morikawa S; Tashiro M; Sakatani M Adv Exp Med Biol; 2006; 581():561-6. PubMed ID: 17037598 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]